Role of membrane transporters in the safety profile of drugs

Bibliography

• Singer S, Nicholson G. The fluid mosaic model of the structure of cell membranes. Science NY 1972;175:720-31
   PubMed Web of Science ®Google Scholar
• Crane RK. Hypothesis for mechanism of intestinal active transport of sugars. Federation Proc 1962;21:891-5
   PubMedGoogle Scholar
• Hediger MA, Ikeda T, Coady M, Expression of size-selected mRNA encoding the intestinal Na/glucose cotransporter in Xenopus laevis oocytes. Proc Natl Acad Sci USA 1987;84(9):2634-7
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455(1):152-62
   PubMed Web of Science ®Google Scholar
• Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009;10(3):218-27
   PubMed Web of Science ®Google Scholar
• Weiner JH, Furlong CE, Heppel LA. A binding protein for L-glutamine and its relation to active transport in E. coli. Arch Biochem Biophys 1971;142(2):715-7
   PubMed Web of Science ®Google Scholar
• Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates [review]. Annu Rev Genomics Hum Genet 2005;6:123-42
   PubMed Web of Science ®Google Scholar
• Harland DN, Garmory HS, Brown KA, Titball RW. An association between ATP binding cassette systems, genome sizes and lifestyles of bacteria. Res Microbiol 2005;156(3):434-42
   PubMed Web of Science ®Google Scholar
• Gbelska Y, Krijger JJ, Breunig KD. Evolution of gene families: the multidrug resistance transporter genes in five related yeast species [review]. FEMS Yeast Res 2006;6(3):345-55
   PubMed Web of Science ®Google Scholar
• Gardner MJ, Hall N, Fung E, Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002;419(6906):498-511
   PubMed Web of Science ®Google Scholar
• Zutz A, Gompf S, Schägger H, Tampé R. Mitochondrial ABC proteins in health and disease. Biochim Biophys Acta 2009. [Epub ahead of print]
   PubMedGoogle Scholar
• Sharom FJ, Liu R, Qu Q, Romsicki Y. Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol 2001;12(3):257-65
   PubMed Web of Science ®Google Scholar
• Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13(16):1859-76
   PubMed Web of Science ®Google Scholar
• Fredriksson R, Nordström KJ, Stephansson O, The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families. FEBS Lett 2008;582(27):3811-6
   PubMed Web of Science ®Google Scholar
• He L, Vasiliou K, Nebert DW. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 2009;3(2):195-206
   PubMedGoogle Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26
   PubMed Web of Science ®Google Scholar
• Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 2008;7(3):205-20
   PubMed Web of Science ®Google Scholar
• Zimmermann C, Gutmann H, Hruz P, Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 2005;33(2):219-24
   PubMed Web of Science ®Google Scholar
• Seithel A, Karlsson J, Hilgendorf C, Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 2006;28(4):291-9
   PubMed Web of Science ®Google Scholar
• Meier Y, Eloranta JJ, Darimont J, Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 2007;35(4):590-4
   PubMed Web of Science ®Google Scholar
• Englund G, Rorsman F, Ronnblom A, Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 2006;29(3-4):269-77
   PubMed Web of Science ®Google Scholar
• Hilgendorf C, Ahlin G, Seithel A, Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007;35(8):1333-40
   PubMed Web of Science ®Google Scholar
• Ji Y, Morris ME. Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004;21(12):2261-9
   PubMed Web of Science ®Google Scholar
• Ji Y, Morris ME. Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein). Mol Pharm 2005;2(5):414-9
   PubMedGoogle Scholar
• Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007;81(4):495-502
   PubMed Web of Science ®Google Scholar
• Shim CK, Cheon EP, Kang KW, Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells. J Pharm Pharmacol 2007;59(11):1515-9
   PubMed Web of Science ®Google Scholar
• Nabekura T, Yamaki T, Kitagawa S. Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1. Eur J Pharmacol 2008;600(1-3):45-9
   PubMed Web of Science ®Google Scholar
• Nabekura T, Yamaki T, Ueno K, Kitagawa S. Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun 2008;369(2):363-8
   PubMed Web of Science ®Google Scholar
• Wang X, Wolkoff AW, Morris ME. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 2005;33(11):1666-72
   PubMed Web of Science ®Google Scholar
• Wang X, Morris ME. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos 2007;35(2):268-74
   PubMed Web of Science ®Google Scholar
• Williams RT. Detoxication Mechanisms. New York: John Wiley & Sons, Inc., 1959
   Google Scholar
• Wilkinson GR. Clearance approaches in pharmacology [review]. Pharmacol Rev 1987;39(1):1-47
   PubMed Web of Science ®Google Scholar
• Petzinger E, Geyer J. Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch Pharmacol 2006;372(6):465-75
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005;33(9):1304-11
   PubMed Web of Science ®Google Scholar
• Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 2007;35(2):293-301
   PubMed Web of Science ®Google Scholar
• Hallifax D, Galetin A, Houston JB. Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica 2008;38(4):353-67
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution [review]. Eur J Pharm Sci 2006;27(5):425-46
   PubMed Web of Science ®Google Scholar
• Funk C. The role of hepatic transporters in drug elimination [review]. Expert Opin Drug Metab Toxicol 2008;4(4):363-79
   PubMed Web of Science ®Google Scholar
• Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) [review]. Drug Discov Today 2008;13(9-10):379-93
   PubMed Web of Science ®Google Scholar
• Smith HW, Goldring W, Chasis H. The measurement of the tubular excretory mass, effective blood flow and filtration rate in the normal human kidney. J Clin Invest 1938;17(3):263-78
   PubMedGoogle Scholar
• Kinsella JL, Holohan PD, Pessah NI, Ross CR. Transport of organic ions in renal cortical luminal and antiluminal membrane vesicles. J Pharmacol Exp Ther 1979;209(3):443-50
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Morisaki T, Sugimoto W, Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury. Drug Metab Dispos 2008;36(4):649-54
   PubMed Web of Science ®Google Scholar
• Nowicki MT, Aleksunes LM, Sawant SP, Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab Lett 2008;2(1):11-7
   PubMedGoogle Scholar
• Warrington JS, Greenblatt DJ, von Moltke LL. The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 2004;309(2):730-6
   PubMed Web of Science ®Google Scholar
• Gupta S. P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging 1995;7(1):19-29
   PubMed Web of Science ®Google Scholar
• Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J 2009;11(2):250-61
   PubMed Web of Science ®Google Scholar
• Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78(3):260-77
   PubMed Web of Science ®Google Scholar
• de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 2003;43:629-56
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3(2):90-105, 51
   PubMedGoogle Scholar
• Youdim KA, Qaiser MZ, Begley DJ, Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 2004;36(5):592-604
   PubMed Web of Science ®Google Scholar
• Liu X, Tu M, Kelly RS, Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos 2004;32(1):132-9
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Read K, Begley DJ, Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 2007;322(1):205-13
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res 2008;25(8):1737-50
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101(2):289-94
   PubMed Web of Science ®Google Scholar
• Sasongko L, Link JM, Muzi M, Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005;77(6):503-14
   PubMed Web of Science ®Google Scholar
• Syvanen S, Lindhe O, Palner M, Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 2009;37(3):635-43
   PubMed Web of Science ®Google Scholar
• Gould GW, Holman GD. The glucose transporter family: structure, function and tissue-specific expression [review]. Biochem J 1993;295( Pt 2):329-41
   PubMedGoogle Scholar
• Shayakul C, Hediger MA. The SLC14 gene family of urea transporters. Pflugers Arch 2004;447(5):603-9
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Aizawa S, Maeda T, Expression of organic cation transporter OCTN1 in hematopoietic cells during erythroid differentiation. Exp Hematol 2004;32(12):1156-62
   PubMed Web of Science ®Google Scholar
• Endres CJ, Moss AM, Ke B, The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther 2009;329(1):387-98
   PubMed Web of Science ®Google Scholar
• Price NT, Jackson VN, Halestrap AP. Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past. Biochem J 1998;329(Pt 2):321-8
   PubMedGoogle Scholar
• Köck K, Grube M, Jedlitschky G, Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy [review]. Clin Pharmacokinet 2007;46(6):449-70
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/cder/guidance/6695dft.pdf
   Google Scholar
• Zhang L, Zhang YD, Strong JM, A regulatory viewpoint on transporter-based drug interactions [review]. Xenobiotica 2008;38(7-8):709-24
   PubMed Web of Science ®Google Scholar
• Ikeguchi M. Water transport in aquaporins: molecular dynamics simulations [review]. Front Biosci 2009;14:1283-91
   Web of Science ®Google Scholar
• Agre P, Saboori AM, Asimos A, Smith BL. Purification and partial characterization of the Mr 30,000 integral membrane protein associated with the erythrocyte Rh(D) antigen. J Biol Chem 1987;262(36):17497-503
   PubMed Web of Science ®Google Scholar
• Benga G. Water channel proteins (later called aquaporins) and relatives: past, present, and future. IUBMB Life 2009;61(2):112-33
   PubMed Web of Science ®Google Scholar
• Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/ transporter interplay and the role of food on drug absorption [review]. Adv Drug Deliv Rev 2008;60(6):717-33
   PubMed Web of Science ®Google Scholar
• Lin JH. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. Curr Drug Metab 2007;8(2):109-36
   PubMed Web of Science ®Google Scholar
• Mather LE. Opioid pharmacokinetics in relation to their effects. Anaesth Intensive Care 1987;15(1):15-22
   PubMed Web of Science ®Google Scholar
• Roden DM, George ALJr. The genetic basis of variability in drug responses. Nat Rev Drug Discov 2002;1(1):37-44
   PubMed Web of Science ®Google Scholar
• Petrovic V, Teng S, Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol Interv 2007;7(2):99-111
   PubMed Web of Science ®Google Scholar
• Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83(6):898-903
   PubMed Web of Science ®Google Scholar
• Lazarowski A, Czornyj L, Lubienieki F, ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007;48(Suppl 5):140-9
   PubMed Web of Science ®Google Scholar
• Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today 2007;12(19-20):838-43
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80(6):565-81
   PubMed Web of Science ®Google Scholar
• Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 2006;78(18):2116-30
   PubMed Web of Science ®Google Scholar
• Alvarez AI, Real R, Perez M, Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 2009 [Epub ahead of print]
   Web of Science ®Google Scholar
• Deferme S, Augustijns P. The effect of food components on the absorption of P-gp substrates: a review. J Pharm Pharmacol 2003;55(2):153-62
   PubMed Web of Science ®Google Scholar
• Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006;45(5):511-42
   PubMed Web of Science ®Google Scholar
• Fenneteau F, Turgeon J, Couture L, Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. Theor Biol Med Model 2009;6:2
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009;328(2):652-62
   PubMed Web of Science ®Google Scholar
• Huang SM, Strong JM, Zhang L, New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008;48(6):662-70
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2005;20(6):452-77
   PubMedGoogle Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2008;23(1):22-44
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJ, van Tellingen O, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77(4):491-502
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, van Deemter L, Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96(4):1698-705
   PubMed Web of Science ®Google Scholar
• Salama NN, Kelly EJ, Bui T, Ho RJ. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J Pharm Sci 2005;94(6):1216-25
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Yano I, Saito H, Inui K. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 2002;300(3):1063-9
   PubMed Web of Science ®Google Scholar
• Wang JS, Taylor R, Ruan Y, Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 2004;29(3):551-7
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Takahashi M, Tamai I, P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res 1999;16(8):1213-8
   PubMed Web of Science ®Google Scholar
• Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003;54(8):840-6
   PubMed Web of Science ®Google Scholar
• Kawahara M, Sakata A, Miyashita T, Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci 1999;88(12):1281-7
   PubMed Web of Science ®Google Scholar
• Oswald S, Koll C, Siegmund W. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice. J Pharm Sci 2007;96(12):3478-84
   PubMed Web of Science ®Google Scholar
• Kido Y, Tamai I, Ohnari A, Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 2001;79(5):959-69
   PubMed Web of Science ®Google Scholar